Skip to Content
Merck
CN

1444279

USP

Mirtazapine

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H19N3
CAS Number:
85650-52-8
Molecular Weight:
265.35
NACRES:
NA.24
PubChem Substance ID:
329750473
UNSPSC Code:
41116107
MDL number:
MFCD00865427

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Mirtazapine, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

SMILES string

CN1CCN2C(C1)c3ccccc3Cc4cccnc24

InChI key

RONZAEMNMFQXRA-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

mirtazapine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... ADRA2A(150), ADRA2B(151), ADRA2C(152), HTR2A(3356), HTR2C(3358)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Mirtazapine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Mirtazapine Tablets
  • Mirtazapine Orally Disintegrating Tablets
  • Mirtazapine Compounded Oral Suspension, Veterinary

Biochem/physiol Actions

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine agonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT1A mediated serotonergic signaling are increased.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H336

Hazard Classifications

Acute Tox. 4 Oral - STOT SE 3

target_organs

Central nervous system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mirtazapine Compounded Oral Suspension, Veterinary
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(5), 2977-2977 (2019)
Mirtazapine
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 37(6), 2976-2976 (2021)
Mirtazapine Orally Disintegrating Tablets
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 37(2), 2980-2980 (2020)
Hun Soo Chang et al.
Journal of neural transmission (Vienna, Austria : 1996), 122(1), 59-68 (2014-12-03)
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is among the most consistent neuroendocrine abnormalities in major depressive disorder (MDD). The peptide adrenocorticotropin hormone (ACTH) mediates HPA axis function during stress and is encoded by the proopiomelanocortin (POMC) gene polycistronically. After screening
Katarzyna Kamińska et al.
Pharmacological reports : PR, 66(6), 984-990 (2014-12-03)
The aim of our study was to understand the mechanism of clinical efficacy of the combination of an antidepressant and risperidone in drug-resistant depression. We studied the effect of an antidepressant (mirtazapine) and risperidone (atypical antipsychotic), given separately or jointly
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service